Dendritic cell (DC)-targeting vaccines show great promise in increasing antitumor immunity. Glycan-engineered vaccines facilitate both DC targeting and increased uptake by DCs for processing and presentation to CD4+ and CD8+ T cells to induce tumor-specific T-cell responses. However, the complexity of various DC subsets in skin tissues, expressing different glycan-binding receptors that can mediate vaccine uptake or drainage of vaccines via lymphatics directly to the lymph node-resident DCs, complicates the success of vaccines. Moreover, the influx of inflammatory immune cells to the site of vaccination, such as monocytes that differentiate to DCs and coexpress glycan-binding receptors, may contribute to the strength of DC-targeting glycovaccines for future clinical use.

中文翻译：

---

化学工程改造的聚糖修饰的癌症疫苗，可动员皮肤树突状细胞。

靶向树突状细胞（DC）的疫苗在提高抗肿瘤免疫性方面显示出广阔的前景。聚糖工程疫苗既促进DC靶向，又促进DC摄取，从而加工并呈递给CD4 +和CD8 + T细胞，以诱导肿瘤特异性T细胞应答。但是，皮肤组织中各种DC亚型的复杂性表达了不同的聚糖结合受体，这些受体可以介导疫苗的摄取或通过淋巴管直接将疫苗引流到位于淋巴结的DC中，这使疫苗的成功复杂化了。此外，炎性免疫细胞向疫苗接种部位的涌入，例如分化为DC并共表达聚糖结合受体的单核细胞，可能有助于靶向DC的糖疫苗的强度，以备将来临床使用。